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Advances in mutation testing for molecular-targeted cancer therapies have led to the increased
use of archived formalin-fixed paraffin-embedded (FFPE) tumors. However, DNA extracted from
FFPE tumors (FFPE DNA) is problematic for mutation testing, especially for amplicon-based mas-
sively parallel sequencing (MPS), owing to DNA fragmentation and artificial C:G > T:A single nucleotide
variants (SNVs) caused by deamination of cytosine to uracil. Therefore, to reduce artificial C:G > T:A
SNVs in amplicon-based MPS using FFPE DNA, we evaluated the efficacy of uracil DNA glycosylase
(UDG) pretreatment, which can eliminate uracil-containing DNA molecules, with 126 archived FFPE
esophageal cancer specimens. We also examined the association between the frequency of
C:G > T:A SNVs and DNA quality, as assessed by a quantitative PCR (qPCR)-based assay. UDG
pretreatment significantly lowered the frequency of C:G > T:A SNVs in highly fragmented DNA
(by approximately 60%). This effect was not observed for good- to moderate-quality DNA, sug-
gesting that a predictive assay (i.e., DNA quality assessment) needs to be performed prior to UDG
pretreatment. These results suggest that UDG pretreatment is efficacious for mutation testing by
amplicon-based MPS with fragmented DNA from FFPE samples.
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Comprehensive genomic studies have revealed genetic vari-
ants in oncogenic driver genes involved in human cancers (1,2).
These findings have facilitated the development of a
classification system of molecular subgroups based on tumor
mutation profiles, which is often utilized as a companion di-
agnostic tool for selecting molecular-targeted therapeutics (3,4).
As more molecular-targeted therapies are developed, com-
prehensive genotyping technologies for identifying clinically
actionable variants across many genes in a single test with
a limited amount of tissue is required (5).
Amplicon-based massively parallel sequencing (MPS) with
next generation sequencing technology is used for this purpose.
This technology includes three amplicon-based methods:
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targeted capture followed by multiplex PCR, multiplex PCR,
and singleplex PCR with digital PCR technologies (6). We pre-
viously reported that the TruSeq Amplicon Cancer Panel
(TSACP) (Illumina, San Diego, CA) using the targeted capture
followed by multiplex PCR method is successful for intact DNA
samples extracted from fresh-frozen surgically resected non-
small cell lung cancer tissues (7).
In most diagnostic laboratories, DNA extracted from formalin-
fixed and paraffin-embedded (FFPE) tumors (FFPE DNA) is
routinely used for mutation testing (8). Moreover, advances
in mutation testing for molecular-targeted therapies have led
to the increased use of archived FFPE samples in clinical prac-
tice (8,9). However, FFPE DNA has limitations for mutation
testing, including amplicon-based MPS, because formalin fixa-
tion, the embedding process, storage conditions, and the
duration of storage cause DNA fragmentation and chemical
modification of DNA molecules (10–13). Various strategies are
used to detect damaged FFPE DNA. To identify DNA samples
with acceptable concentrations and lengths for amplicon-
based MPS, both DNA quantification with fluorometric detection
reagents specific for double-stranded DNA (dsDNA) and quan-
titative PCR (qPCR)-based assessment for DNA fragmentation
have been recognized as effective strategies (9,14–16). Fur-
thermore, artificial C:G > T:A single nucleotide variants (SNVs),
caused by deamination of cytosine to uracil, have significant
implications for the accuracy of mutation testing (11,12).
C:G > T:A SNVs are the predominant SNV type observed in
FFPE DNA (11,17,18), and uracil DNA glycosylase (UDG) pre-
treatment can effectively reduce their prevalence by degrading
uracil-containing DNA molecules (17,19). Moreover, the effi-
cacy of UDG pretreatment in amplicon-based MPS with FFPE
DNA has been reported by Do et al. (18) using FFPE DNA
extracted from three squamous cell lung cancer tumors, and
by Wong et al. (20) using FFPE DNA extracted from two breast
cancer tumors and one melanoma. However, there are cur-
rently no comparisons of sequencing quality or accuracy of
amplicon-based MPS between UDG-pretreated and un-
treated samples, using FFPE DNA obtained from a
considerable number of patients.
Therefore, in this study, we evaluated the efficacy of UDG
pretreatment for amplicon-based MPS with FFPE DNA using
126 archived FFPE esophageal cancer specimens. More-
over, we examined the association between the frequency of
artificial C:G > T:A SNVs and DNA quality (as determined by
qPCR) with respect to DNA fragmentation.
Materials and methods
Tissue samples
FFPE tissue samples were obtained from 135 patients who
had esophageal cancer and underwent surgery at the Shi-
zuoka Cancer Center (118 samples) or University of Toyama
(17 samples) between October 2002 and November 2011
(Supplementary Table S1). Formalin fixation and embedding
were routinely performed at each institute with 10% forma-
lin. FFPE specimens were macrodissected by pathologists to
enrich the tumor content for DNA extraction. The study pro-
tocol was approved by both institutional review boards (approval
numbers: Shizuoka Cancer Center, T23-3; Toyama Univer-
sity, 22-96).
Genomic DNA extraction
Tumor samples with a diameter of 2 mm were punched out
from the paraffin block and deparaffinized by incubation with
xylene at room temperature for 4 hours. A QIAamp DNA
FFPE tissue kit (Qiagen, Venlo, Netherlands) was used to
extract genomic DNA from FFPE tumors according to the
manufacturer’s instructions. The median time from surgical
resection to DNA extraction (i.e., storage duration) was 5.5
years (range, 1.3–10.3 y; Supplementary Table S1). DNA
concentration was determined using a dsDNA quantification
kit (Life Technologies Quant-iT PicoGreen dsDNA assay kit;
Thermo Fisher Scientific, Waltham, MA) (Supplementary
Table S1).
Assessment of DNA fragmentation with a qPCR-
based assay
A qPCR-based assessment of DNA fragmentation in FFPE
DNA was performed using the Life Technologies StepOnePlus
real-time PCR system (Thermo Fisher Scientific), 4 ng of
genomic DNA, SYBR Premix Ex Taq II (Tli RNaseH Plus;
Takara Bio, Shiga, Japan), and the QC primer reagent from
the Illumina FFPE QC Kit, according to the manufacturer’s in-
structions. Average ΔCt (cycle threshold) values were calculated
by subtracting the Ct value of the control sample from that of
each sample in the three experiments (Supplementary
Table S1).
Amplicon-based MPS with TSACP
Amplicon-based MPS was performed on the MiSeq se-
quencer (Illumina) using the TSACP (Illumina), which is
designed to detect somatic mutations in 48 cancer-related
genes (Supplementary Table S2), according to the manufac-
turer’s instructions. A volume of 5 µL of genomic DNA
(median concentration 74.3 ng/µL, range 6.6–124.0 ng/µL;
Supplementary Table S1) was used to amplify 212 amplicons
targeting the hotspot regions of these 48 genes and for index
library construction. The concentration of the resultant library
was adjusted with library normalization beads (LNB1, Illumina),
and equal volumes of every 32 samples were pooled for one
sequencing run to obtain 1,000× or greater coverage (desired
average coverage per sample according to the manufactur-
er’s instructions). Paired-end sequencing for 32 samples per
run was performed on an Illumina MiSeq platform with the
MiSeq Reagent Kit v2 (300 cycles) (Illumina). To obtain 3.5
Gigabases (Gb) or more of total sequencing output per run
with a quality score of greater than Q30, the pooled library
volume used for sequencing was optimized.
UDG pretreatment
UDG pretreatment was performed as described by Do et al.
(18). DNA samples were incubated with 2.5 µL (12.5 U) of UDG
(New England Biolabs, Beverly, MA) for a final volume of 10 µL
containing 1 µL of 10× UDG Reaction buffer (New England
Biolabs), 1.5 µL of distilled water (Thermo Fisher Scientific),
and 5 µL of genomic DNA for 3 hours at 37°C. The UDG
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enzyme was inactivated at 95°C for 10 minutes and stored
at −80°C until use in the TSACP assay. An equal amount of
DNA sample (same as that used for library preparation in the
non–UDG-pretreated sample) was used for UDG pretreat-
ment (Supplementary Table S1). All reactions were performed
on the Life Technologies Veriti 96-well thermal cycler (Thermo
Fisher Scientific).
Data analysis for amplicon-based MPS with the
TSACP assay
Data were processed using CLC Genomics Workbench version
7.0.4 (CLC bio, Aarhus, Denmark). Quality-trimmed se-
quence reads were mapped onto the human genome (hg19).
Variants showing 20 read counts or fewer detected in the
TSACP assay are likely to include miscalled variants result-
ing from a sequencing error (data not shown). Therefore, to
retain detection sensitivity equivalent to or greater than that
of Sanger sequencing (detection sensitivity 15–25% (21,22))
in the TSACP assay, the minimum criterion for average
coverage to select samples that meet our sequencing quality
threshold was set at greater than 100×. Variants showing
allele frequencies of 5% or more with 250× or greater cov-
erage (bidirectional) per base were selected as candidate
variants, as proposed by Luthra et al. (23). This criterion is
used for clinical reporting based on the results of TSACP
assays (23). From these selected candidate variants, puta-
tive somatic variants were selected by filtering out germline
mutations on the basis of information from HapMap (24)
and the Human 1,000 Genomes Project (25). Then,
nonsynonymous mutations were selected from the putative
somatic variants on the basis of the hg19 CDS (coding DNA
sequence) file. The remaining variants (after the described
filtering process) were annotated using the Catalogue of
Somatic Mutations in Cancer (COSMIC) v67 (26), a leading
database of somatic variants involved in cancer. Finally, the
somatic variants listed in the COSMIC database were se-
lected and considered reliable. Among the COSMIC
nonsynonymous somatic variants detected, we focused on
SNVs to evaluate the effect of UDG pretreatment on the
artificial C:G > T:A SNVs in FFPE DNA in this study.
Validation of the results obtained in the
TSACP assay
Testing with the Illumina TruSight tumor panel (TSTP),and Life
Technologies TaqMan mutation detection assays (Thermo
Fisher Scientific) was performed to validate the results ob-
tained in the TSACP assay (see Supplementary Methods for
details).
Statistical analysis
Two-sided Student t tests, Fisher exact tests, and Spear-
man rank correlation coefficient tests were performed with
GraphPad Prism 5 (GraphPad Software, San Diego, CA). A
P value less than 0.01 indicated a statistically significant dif-
ference. Receiver operating characteristic (ROC) analysis was
performed with JMP 9.0 (SAS Institute, Cary, NC).
Results
Prior assessment of DNA quality for amplicon-
based MPS with the TSACP assay
We could extract detectable dsDNA in 134 of 135 esopha-
geal cancer FFPE tissue samples using the Life Technologies
PicoGreen assay (Thermo Fisher Scientific) for dsDNA-
specific quantification (Supplementary Table S1).
DNA fragmentation in these 134 FFPE DNA samples was
assessed by a qPCR-based assay, and the ΔCt value (ΔCt)
was obtained as described in the Materials and methods
section. ΔCt serves as an index that is positively correlated
with the degree of DNA fragmentation. The median of the
average ΔCt for 134 samples was 1.0 (range, −1.02 to 6.04;
Supplementary Figure S1, Supplementary Table S1), and ap-
proximately 75% of the samples (101/134) showed ΔCt less
than or equal to 2.0, which is the prescribed criterion for sample
selection for the TSACP assay (Supplementary Figure S1
and Supplementary Table S1). Although storage duration is
related to DNA fragmentation in FFPE DNA (20), there was
no significant difference in the storage duration of the FFPE
tumors between samples showing ΔCt of 2.0 or less and ΔCt
greater than 2.0 (mean 5.7 vs. 6.4; P = .1813; Supplementary
Figure S2). This result indicated that storage duration did
not influence the quality of FFPE DNA used in this study.
The 134 FFPE DNA samples were tested with the TSACP
assay to evaluate the association between ΔCt and sequenc-
ing quality.
Results of qPCR-based DNA quality assessment
reflect sequencing quality
The TSACP assay of 134 FFPE DNA samples identified
eight samples with less than 100× average coverage for
non–UDG-pretreated or UDG-pretreated samples or both.
These samples were omitted from subsequent analysis
(Supplementary Table S1). Among these eight samples, ΔCt
in seven samples was greater than 4.0 (Supplementary
Figure S3), indicating that samples with ΔCt of 4.0 or greater
should be excluded from the TSACP assays.
Sequence quality check (QC) metrics obtained from the
results of the TSACP assay with 126 samples were used for
subsequent evaluation (Table 1 and Supplementary Table S1).
In all sequence QC metrics, the 101 samples with ΔCt of 2.0
or less had significantly higher sequence QC metric values
than the 25 samples with ΔCt greater than 2.0 (Table 1), in-
dicating that ΔCt of 2.0 or less is a suitable criterion to select
samples that show acceptable sequencing quality. Subse-
quently, we evaluated the association between ΔCt and each
of the sequence QC metrics. The sequence QC metrics were
inversely correlated with ΔCt (Figure 1), and sequencing quality
declined as DNA fragmentation increased. There was no cor-
relation between DNA concentration and the sequence QC
metrics (data not shown), indicating that DNA quality, but not
DNA concentration, has a causal influence on sequencing
quality. These observations demonstrate that assessment of
DNA fragmentation with a qPCR-based assay can be used
to predict sequencing quality and that it is necessary to elimi-
nate low quality samples for TSACP assays.
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Table 1 Comparison of sequence QC metrics between non–UDG-pretreatment and UDG-pretreatment groups
Non-UDG pretreatment UDG pretreatment
P valueaMean (95% CI) Median Range Mean (95% CI) Median Range
Total reads (millions) All 1.223 (1.026–1.421) 0.906 0.061–6.652 1.151 (1.036–1.267) 1.105 0.08–2.515 0.5336
ΔCt ≤ 2 1.397 (1.166–1.628) 1.073 0.061–6.652 1.349 (1.236–1.461) 1.35 0.085–2.515 0.7099
ΔCt > 2 0.523 (0.342–0.704) 0.319 0.09–1.851 0.354 (0.252–0.456) 0.274 0.08–0.848 0.1010
ΔCt ≤ 2 vs. ΔCt > 2b 0.0004 <0.0001
Total reads after quality-
based trimming
(millions)
All 1.223 (1.025–1.42) 0.906 0.061–6.65 1.151 (1.035–1.266) 1.105 0.08–2.515 0.5338
ΔCt ≤ 2 1.396 (1.165–1.627) 1.073 0.061–6.65 1.348 (1.235–1.461) 1.349 0.085–2.515 0.7102
ΔCt > 2 0.522 (0.341–0.704) 0.319 0.09–1.85 0.354 (0.252–0.456) 0.274 0.08–0.848 0.1008
ΔCt ≤ 2 vs. ΔCt > 2b 0.0004 <0.0001
Mapped reads on
targeted regions
(millions)
All 1.157 (0.967–1.347) 0.825 0.042–6.356 1.089 (0.977–1.202) 1.057 0.053–2.433 0.5431
ΔCt ≤ 2 1.332 (1.11–1.554) 1.016 0.042–6.356 1.281 (1.172–1.39) 1.307 0.063–2.433 0.6835
ΔCt > 2 0.451 (0.287–0.615) 0.284 0.048–1.504 0.314 (0.215–0.413) 0.241 0.053–0.799 0.1458
ΔCt ≤ 2 vs. ΔCt > 2b 0.0002 <0.0001
Proportion of mapped
reads (%)
All 91.8 (90.26–93.33) 95 52.3–98 92.28 (90.96–93.6) 94.9 47–97.7 0.6414
ΔCt ≤ 2 94.29 (93.39–95.18) 95.5 68.6–98 94.32 (93.52–95.13) 95.6 71.1–97.7 0.9570
ΔCt > 2 81.74 (76.24–87.24) 85.6 52.3–97.5 84.01 (79.23–88.79) 86.4 47–94.8 0.5230
ΔCt ≤ 2 vs. ΔCt > 2b <0.0001 <0.0001
Average coverage
(reads/base)
All 4,705 (3,918–5,491) 3,259 169.5–26,097 4,322 (3,868–4,776) 4,233 176.2–10,040 0.4046
ΔCt ≤ 2 5,434 (4,517–6,351) 4,086 169.7–26,097 5,094 (4,651–5,536) 5,191 235.4–10,040 0.5078
ΔCt > 2 1,758 (1,096–2,420) 1,064 169.5–6,081 1,203 (805.8–1,600) 919.5 176.2–3,214 0.1442
ΔCt ≤ 2 vs. ΔCt > 2b 0.0002 <0.0001
Data in bold indicate statistically significant differences.
a Results of two-sided paired t-test. (Non-UDG pretreatment vs. UDG pretreatment).
b Results of two-sided Student t-test (ΔCt ≤ 2 vs. ΔCt > 2, based on the results of qRT-PCR-based quality assessment assay using Illumina FFPE QC kit).
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Figure 1 Correlation between each QC metric output from the TSACP assay and ΔCt values from the qPCR-based assessment of
DNA fragmentation. All sequence QC metrics, including (A) total reads, (B) total reads after quality-based trimming, (C) mapped reads
on targeted regions, (D) proportion of mapped reads, and (E) average coverage were inversely correlated with ΔCt in non–UDG-
pretreated and UDG-pretreated samples. UDG pretreatment increased the magnitude of these correlations. These associations were
evaluated using the Spearman rank correlation coefficient test.
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Effect of UDG pretreatment on sequencing quality
in the TSACP assay
UDG pretreatment effectively improves the accuracy of
amplicon-based MPS with FFPE DNA because it reduces the
number of C:G > T:A SNVs, which are the predominant type
of artificial SNVs observed in FFPE DNA (18). Thus, in order
to implement UDG pretreatment in clinical sequencing with
archived FFPE DNA, the effect of UDG pretreatment on se-
quencing quality in the TSACP assay needed to be evaluated.
We did not observe any significant difference between the two
treatment groups for any of the sequence QC metrics con-
sidered, for not only the 101 samples with ΔCt of 2.0 or less
but also the 25 samples with ΔCt greater than 2.0 (Table 1).
These results suggest that there are no remarkable differ-
ences between the libraries generated from non–UDG-
pretreated and UDG-pretreated DNA. However, all sequence
QC metrics obtained from UDG-pretreated samples showed
slightly less variation than those obtained from non–UDG-
pretreated samples (Table 1, Figure 1). Moreover, the inverse
correlations between ΔCt and each sequence QC metric ob-
served in the UDG-pretreated samples (except for proportion
of mapped reads) were greater in magnitude than those ob-
served in the non–UDG-pretreated samples (Figure 1). These
results imply that degradation of uracil-containing DNA mol-
ecules by UDG pretreatment can minimize and remove
damaged DNA molecules in FFPE DNA and improve the ef-
ficiency of the PCR process in the TSACP assay, ultimately
resulting in improved sequencing quality.
UDG pretreatment effectively reduced the
prevalence of C:G > T:A SNVs detected in severely
damaged FFPE DNA
Considering nonsynonymous COSMIC-registered SNVs with
allele frequencies of 5% or more and 250× or greater cover-
age per base, 358 and 222 SNVs were detected in the non–
UDG-pretreated and UDG-pretreated samples, respectively
(Supplementary Table S4). These SNVs were used in sub-
sequent evaluations as reliable somatic SNVs.
Figure 1. (continued )
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Figure 2 shows the association between ΔCt (which re-
flects the sequencing quality in the TSACP assay) and the
number of SNVs detected in each non–UDG-pretreated and
UDG-pretreated sample. A positive correlation between ΔCt
and the number of SNVs was commonly observed within both
treatment groups (Figure 2), implying that the accumulation
of damaged DNA molecules is correlated with increased op-
portunity for sequencing artifacts. Moreover, ROC analysis
revealed that the number of SNVs detected in the UDG-
pretreatment group tended to be lower than that detected in
the non–UDG-pretreatment group for samples with ΔCt of 1.20
or greater (Figure 2).
These observations were verified by comparing the change
in the cumulative number of detected SNVs with an in-
crease in ΔCt between the treatment groups (Figure 3,
Supplementary Table S5). The cumulative number of de-
tected SNVs in the UDG-pretreated samples was lower than
that in the non-UDG-pretreated samples when ΔCt was 1.55
or greater (Figure 3, Supplementary Table S5). This differ-
ence between the two treatment groups was thought to be
mainly caused by dramatic UDG-pretreatment-induced re-
duction in the cumulative number of C:G > T:A SNVs when
ΔCt was 1.55 or greater (Figure 3G, Supplementary Table S5).
Therefore, we focused on ΔCt of 1.55 as a potential criterion
to discriminate whether sequencing artifacts that could not be
ignored were included, and we compared the prevalence of
each type of SNV in 88 samples showing ΔCt less than 1.55
and 38 samples showing ΔCt of 1.55 or greater (Figure 4).
C:G > T:A SNVs were the predominant type of SNVs in both
ΔCt groups (Figure 4). In particular, the prevalence of C:G > T:A
SNVs in samples that have ΔCt of 1.55 or greater was strik-
ingly higher than that of other types of SNVs in both treatment
groups (Figure 4B), indicating that the frequency of C:G > T:A
artificial SNVs in FFPE DNA was closely associated with the
degree of DNA fragmentation. Moreover, remarkable reduc-
tion in the prevalence of C:G > T:A SNVs because of UDG
pretreatment was observed only in samples showing ΔCt of
1.55 or greater (Figure 4B), but not in samples showing ΔCt
less than 1.55 (Figure 4A). These results suggest that UDG
pretreatment is an effective approach to reduce the preva-
lence of C:G > T:A SNVs in severely fragmented FFPE DNA.
Moreover, UDG pretreatment had little effect on samples
showing ΔCt less than 1.55 (Figure 4A), indicating that UDG
pretreatment is not necessary for such samples. Therefore,
ΔCt of 1.55 may be used as a cutoff to determine whether
UDG pretreatment for FFPE DNA is necessary.
Validation of the results obtained in the
TSACP assay
The median allele frequencies of SNVs unique to each non–
UDG-pretreated and UDG-pretreated sample were less than
8% (Supplementary Figure S4), which is significantly lower
than those of commonly detected SNVs in both non–UDG-
pretreated and UDG-pretreated samples (Supplementary
Figure S4). Artificial calls are more frequently observed when
the allele frequency is less than 10% (18,20), implying that
Figure 2 Positive correlation between the numbers of single nucleotide variants (SNVs) detected in the TSACP assay and ΔCt values
from the qPCR-based assessment of DNA fragmentation. These associations were evaluated using the Spearman rank correlation
coefficient test. The number of SNVs detected in (A) non–UDG-pretreated samples tended to be higher than that detected (B) after
UDG pretreatment showing ΔCt ≥ 1.20, as calculated by ROC analysis (sensitivity = 0.9091, specificity = 0.8065, area under the
curve = 0.90046).
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SNVs unique to each non–UDG-pretreated and UDG-
pretreated sample might include false positives.
Therefore, we performed testing with the TSTP to vali-
date the results obtained in the TSACP assay. The TSTP
enables the determination of C:G > T:A type SNVs resulting
from cytosine deamination as false-positive variants by se-
quencing both DNA strands independently. In addition,
C:G > T:A SNV calling for six clinically relevant positions was
also validated with the TSTP (Table 2) and the TaqMan
mutation detection assay (Table 2 and Supplementary
Figure S5).
Thirty-two non–UDG-pretreated samples with ΔCt of 1.55
or greater harboring SNVs detected by TSACP within the over-
lapping target region of TSACP and TSTP testing were used
for the validation (Supplementary Table S2 and Figure 5). Of
29 SNVs, 28 (97%) commonly detected by TSACP in both
non–UDG-pretreated and UDG-pretreated samples were con-
firmed by the TSTP results (Figure 5), and six SNVs in PIK3CA
commonly detected in both non–UDG-pretreated and UDG-
pretreated samples by TSACP were confirmed by both
validation assays (Table 2), suggesting that the SNVs com-
monly detected in both non–UDG-pretreated and UDG-
pretreated samples were reliable. Meanwhile, 151 of 158 (96%)
and 56 of 60 (93%) SNVs detected by TSACP uniquely in non–
UDG-pretreated and UDG-pretreated samples, respectively,
were not confirmed by the TSTP results (Figure 5), suggest-
ing that most of the SNVs detected by TSACP uniquely in the
non–UDG-pretreated and UDG-pretreated samples were false
positives. Given the significant reduction in the number of false
positives (approximately 63%, from 151 to 56) (Figure 5), UDG
pretreatment appears to be beneficial. Among seven clini-
cally relevant SNVs detected by TSACP uniquely in non–
UDG-pretreated samples, five SNVs were not confirmed in
either the TaqMan assay or the TSTP results (Table 2), again
suggesting a higher incidence of false positives in the absence
of UDG pretreatment.
Figure 3 Change in the cumulative number of detected SNVs with increased ΔCt for non–UDG-pretreated and UDG-pretreated samples.
The cumulative number of C:G > T:A SNVs detected for the two treatment groups was significantly different in samples with ΔCt ≥ 1.55.
(A) All types, (B) A:T > C:G, (C) A:T > G:C, (D) A:T > T:A, (E) C:G > A:T, (F) C:G > G:C, (G) C:G > T:A.
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Meanwhile, seven SNVs uniquely detected in non–UDG-
pretreated samples were verified with TSTP testing (Figure 5),
indicating that these SNVs were true variants that may have
been lost because of the nonspecific effect of UDG pretreat-
ment (approximately 4% of the 187 SNVs detected in the non–
UDG-pretreated samples). These results indicate that UDG
pretreatment provides benefits for significant reduction in the
number of false positives, though a handful of true variants
may be lost.
Effect of UDG pretreatment on C > T SNVs at CpG
dinucleotide sites
As we have described, UDG pretreatment is an effective ap-
proach to overcome cytosine deamination in FFPE DNA.
However, C > T SNVs in methylated CpG dinucleotide sites
are resistant to UDG pretreatment (18). Cytosine residues at
CpG dinucleotide sites are methylated, and the resultant
5-methylcytosine is subsequently deaminated to thymine. UDG
pretreatment acts on uracil residues but not on thymine resi-
dues (18).
Therefore, we compared the prevalence of C > T SNVs at
each CpN (CpA, CpC, CpG, and CpT) dinucleotide site in
samples with C:G > A:T SNVs between the non–UDG-
pretreatment and UDG-pretreatment groups (Figure 6). G > A
SNVs were tallied for the opposite strand. In UDG-pretreated
samples with ΔCt less than 1.55, 73%, 40%, and 74% of the
non–UDG-pretreated samples with C:G > A:T SNVs had C > T
SNVs in CpA, CpC, and CpG dinucleotide sites, respec-
tively (Figure 6A), suggesting that many CpG dinucleotide sites,
where C:G > A:T SNVs were detected, are not methylated.
Moreover, a significant reduction of the prevalence of C > T
SNVs was observed on UDG pretreatment for not only the
CpA, CpC, and CpT sites but also the CpG sites, in samples
with ΔCt of 1.55 or greater, which were significantly affected
by UDG pretreatment (Figure 6B). This observation is not
consistent with the results reported in a previous study (18).
The number of C > T SNVs detected in UDG-pretreated
samples relative to that in non–UDG-pretreated samples was
slightly higher at CpG dinucleotide sites than that at other types
of dinucleotide sites (CpA 3.6%, CpC 5.9%, CpG 18.8%, CpT
0.0%; Figure 6B). This finding suggests a weak tendency for
C > T SNVs at the CpG dinucleotide to be insusceptible to
UDG pretreatment. Despite this limitation, UDG pretreat-
ment remarkably reduces the overall prevalence of C > T SNVs
caused by cytosine deamination in FFPE DNA and is there-
fore an effective approach for overcoming the limitations of
FFPE DNA.
Discussion
In this study, we examined whether UDG pretreatment using
qPCR-based DNA quality assessment can mitigate the major
limitations of mutation testing with damaged FFPE DNA, such
as DNA fragmentation and presence of C:G > T:A artificial SNVs
caused by deamination of cytosine to uracil.
DNA fragmentation was assessed, and ΔCt was found to
be significantly associated with the sequence QC metrics in
the TSACP assay (Figure 1) and the frequency of sequenc-
ing artifacts such as C:G > T:A SNVs (Figures 2 and 3).
Therefore, ΔCt reflects the overall sequencing quality in the
TSACP assay. These observations indicate that accumula-
tion of fragmented DNA molecules in FFPE DNA is closely
correlated with the occurrence of sequencing artifacts. Wong
et al. (20) also demonstrated this association using TaqMan
PCR of FTH1 (to assess DNA fragmentation) and TSACP
assays. However, they did not investigate whether the FTH1
copy number could be used as an objective criterion for the
selection of FFPE DNA, considering sequencing artifacts such
as C:G > T:A SNVs. Sah et al. (16) also reported an asso-
ciation between DNA quality and frequency of sequencing
artifacts with another amplicon-based MPS method, Life
Figure 4 The prevalence of each type of COSMIC-registered SNV in samples with (A) ΔCt < 1.55 and (B) ΔCt ≥ 1.55. The preva-
lence of the six types of SNVs in each ΔCt category was classified as non–UDG pretreatment only (uniquely detected in non–UDG-
pretreated samples), common (commonly detected in both non–UDG-pretreated and UDG-pretreated samples), and UDG pretreatment
only (uniquely detected in UDG-pretreated samples). UDG pretreatment showed approximately 60% reduction in the prevalence of
C:G > T:A SNVs, (A) not in samples with ΔCt < 1.55 and (B) only in damaged DNA with ΔCt ≥ 1.55.
UDG pretreatment in amplicon-based massively parallel sequencing of FFPE DNA 423
Table 2 Validation of clinically relevant C:G > T:A SNVs detected by the TSACP assay
SNV Sample ID ΔCta
The treatment
conditions that SNVs
showing allele
frequency of ≥5% with
≥250× coverage per
base were detectedb
TSACP
Non–UDG pretreatment
TSACP
UDG pretreatment TSTP
TaqMan mutation
detection assay
Total
reads
Variant
reads
Variant
(%)
Total
reads
Variant
reads
Variant
(%)
Variant
(%)
Non–UDG
pretreatment
UDG
pretreatment
KRAS G12S
(chr12:25398285,
C > T)
8 2.25 No 553 92 16.6 139 0 0.0 18.3 − −
54 1.55 No 1,214 73 6.0 932 0 0.0 ND − −
NRAS G12S
(chr1:115258748,
C > T)
15 1.87 No 1,419 90 6.3 1,445 0 0.0 ND − −
NRAS G12D
(chr1:115258747,
C > T)
21 3.13 No 1,475 121 8.2 219 0 0.0 ND − −
NRAS G13D
(chr1:115258744,
C > T)
T10 2.03 No 2,752 150 5.5 2,146 4 0.2 ND − −
PIK3CA E542K
(chr3:178936082,
G > A)
31 2.70 No/Yes 1,069 146 13.7 1,832 560 30.6 10.9 + +
35 1.08 (No)/Yesc 13,772 616 4.5 6,702 413 6.2 4.9 + +
T19 3.13 No/Yes 657 80 12.2 1,488 286 19.2 13.2 + +
PIK3CA E545K
(chr3:178936091,
G > A)
8 2.25 No 3,474 194 5.6 1,147 2 0.2 ND − −
9 1.46 No/Yes 5,249 543 10.3 6,127 696 11.4 16.8 + +
17 1.00 No/Yes 7,177 1,083 15.1 6,397 958 15.0 22.7 + +
30 1.58 No 5,243 331 6.3 2,676 11 0.4 4.4 + +
T12 0.48 No/Yes 9,588 2,219 23.1 7,194 1,540 21.4 36.7 + +
Abbreviations: +, positive in TaqMan mutation detection assay; −, negative in TaqMan mutation detection assay; ND, not detected; No, Detected in non-UDG-pretreated sample; Yes, Detected
in UDG-pretreated sample.
a Samples with a ΔCt value of ≥1.55 in Illumina FFPE QC kit are shown in bold.
b SNVs with an allele frequency of ≥5% with ≥250× coverage per base detected by TSACP with non–UDG-pretreated (No) or UDG-pretreated (Yes) samples or both.
c The allele frequency of PIK3CA E542K in non–UDG-pretreated samples of patient 35 is slightly less than 5%. However, this SNV was confirmed to represent a positive SNV by visual
inspection of mapping data.
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Technologies AmpliSeq cancer panel (Thermo Fisher Scien-
tific), using a quantitative functional index (QFI)–PCR method
based on multiplex PCR. They determined the QFI thresh-
old value that can be used to identify samples with sequencing
artifacts with high probability (16). qPCR-based preanalytical
DNA quality assessment is commonly used in amplicon-
based MPS to ensure high sequencing quality.
To our knowledge, this study is the most comprehensive
evaluation of UDG pretreatment for amplicon-based MPS with
FFPE DNA to date. We also confirmed the efficacy of UDG
pretreatment in reducing C:G > T:A SNVs, which are the pre-
dominant type of sequencing artifacts observed in FFPE DNA;
our results are consistent with those of previous reports (18,20).
UDG pretreatment effectively reduced the number of C:G > T:A
SNVs, especially in samples with ΔCt of 1.55 or greater, but
not in samples with ΔCt less than 1.55 (Figure 4), indicating
that UDG pretreatment is effective for severely fragmented
FFPE DNA. Therefore, in addition to the criterion of ΔCt of
2.0 or less described in the manufacturer’s instructions, ΔCt
of 1.55 may be also used to determine whether UDG pre-
treatment for FFPE DNA is necessary. To our knowledge, this
is the first report to propose an objective criterion (ΔCt = 1.55)
for selecting FFPE DNA that requires UDG pretreatment. To
evaluate the applicability of this cutoff value, further evalua-
tion of the effect of UDG pretreatment on each stratified group
of another cohort based on this criterion is necessary.
The prevalence of C:G > T:A SNVs detected in the samples
was remarkably high even after UDG pretreatment (60.4%)
(Figure 4), compared with that reported in a previous study
using whole exome sequencing of intact DNA extracted from
surgically resected fresh-frozen esophageal cancer tissues
(45.2% of all detected putative somatic SNVs showing an allele
frequency of 5% or more) (27). There are at least two expla-
nations for this difference. First, because the TSACP assay
was an amplicon-based MPS assay targeting hotspot regions
of cancer-related genes, it is possible that the variant detec-
tion efficiency of the TSACP assay was higher than that of
whole exome sequencing. Second, we used only COSMIC-
based filtering to select tumor-specific somatic SNVs, which
may be biased toward C:G > T:A SNVs. In the case of
nonsynonymous putative somatic SNVs, including those not
registered in COSMIC, the prevalence of C:G > T:A SNVs in
the non–UDG-pretreated FFPE DNA samples was 71.5% (data
not shown), whereas that in the UDG-pretreated samples was
46.3% (data not shown), which is similar to that reported
Figure 5 Validation assay with TSTP for SNVs detected in
TSACP using 32 samples showing ΔCt ≥ 1.55. The degree of con-
cordance between TSTP and TSACP results was classified as
non–UDG pretreatment only (uniquely detected in non–UDG-
pretreated samples), common (commonly detected in both non–
UDG-pretreated and UDG-pretreated samples), and UDG
pretreatment only (uniquely detected in UDG-pretreated samples).
Most SNVs uniquely detected in each pretreatment group were
false-positive variants in the TSACP assay with FFPE DNA. UDG
pretreatment resulted in a drastic reduction of the number of false
positives (approximately 63%, from 151 to 56).
Figure 6 The prevalence of C > T SNVs at CpN (CpA, CpC, CpG, and CpT) dinucleotide sites in samples showing ΔCt < 1.55 (A)
and ΔCt ≥ 1.55 (B). G > A SNVs were tallied for the opposite strand. Most CpG dinucleotide sites where C:G > A:T SNVs were de-
tected are not methylated.
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previously using whole exome sequencing (45.2%) (27). These
results suggest that UDG pretreatment improves the sequenc-
ing accuracy of the TSACP assay with FFPE DNA by reducing
the number of artificial C:G > T:A SNVs caused by cytosine
deamination.
One of the limitations of this study is that, because the fresh-
frozen samples obtained from corresponding surgically resected
tumors used in this study had not been archived, we could
not evaluate the efficacy of UDG pretreatment by comparing
the prevalence of each type of SNV in UDG-pretreated FFPE
DNA with that in intact DNA isolated from the samples as-
sessed in this study. To further evaluate the efficacy of UDG
pretreatment, we plan to use both fresh-frozen and FFPE
samples derived from the same surgically resected banked
tumors in another prospective study. Instead, in this study, we
performed testing with the TaqMan assay and TSTP to verify
the results obtained from the TSACP assay (Table 2 and
Figure 5). Although a handful of true variants were lost with
UDG pretreatment, we were able to significantly reduce the
number of false positives caused by cytosine deamination
(Figure 5), thereby validating the advantage of UDG pretreat-
ment in severely damaged DNA. In order to maximize this effect
of UDG pretreatment, it is necessary to avoid the loss of true
variants by establishing better criteria for the requirement for
UDG pretreatment.
In this study, we demonstrated that the combination strat-
egy of qPCR-based DNA quality assessment and UDG
pretreatment to overcome limitations of FFPE DNA such as
DNA fragmentation and artificial C:G > T:A SNVs is simple and
effective. This combination of methods improves the sequenc-
ing accuracy of the TSACP assay implemented with damaged
FFPE DNA. Moreover, we found that this combination strat-
egy provides objective criteria to determine the need for UDG
pretreatment in the TSACP assay. Therefore, this combina-
tion strategy should be incorporated into clinical sequencing
protocols to facilitate personalized cancer medicine based on
more accurate mutational information obtained from ar-
chived FFPE tumors.
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